| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2801962901019 | 196290101 | ZOLADEX INJ.IMPL 3.6 MG/PF.SYR BTx1 PF.SYR. +SAFE SYSTEM SYSTEM | 51.22 | 53.73 | 68.35 |
| 05/2018 | 2801962902016 | 196290201 | ZOLADEX INJ.IMPL 10,8MG/PF.SYR. BTx1PF.SYR. +SAFE SYSTEM SYSTEM | 170.64 | 179.00 | 216.30 |
Breast cancer; Prostate carcinoma; Endometriosis
ZOLADEX is a synthetic decapeptide analogue of LHRH. ZOLADEX acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.
No experience of overdosage from clinical trials
Inactive orally, rapidly absorbed following subcutaneous administration
4-5 hours
Clearance of goserelin following subcutaneous administration of a radiolabeled solution of goserelin was very rapid and occurred via a combination of hepatic and urinary excretion. More than 90% of a subcutaneous radiolabeled solution formulation dose of goserelin was excreted in urine.
* 44.1 ± 13.6 L [subcutaneous administration of 250 mcg]
* 121 +/- 42.4 mL/min [prostate cancer with 10.8 mg depot]